ErbB2 is a target of chemotherapy in the treatment of several cancers and the inhibition of ErbB2 signaling by transgenic knock-out in mice and herceptin-treatment humans is associated with the development of dilated cardiomyopathy [51]–[53]. The gene discussed is ERBB2; the disease is dilated cardiomyopathy.